patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_923788 | REC_0015601 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 14 | 9.6 | 70 | female | 2 | 19 | 5.5 | 0 | sotorasib 960 mg daily | 43.7 | true | MSS | 2026-03-15T05:36:01.343436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532959 | REC_0015602 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.7 | 51 | female | 0 | 30 | 8.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.343869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693889 | REC_0015603 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.7 | 70 | male | 1 | 15 | 6.5 | 6 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:36:01.344322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401410 | REC_0015604 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.6 | 72 | female | 2 | 12 | 4.3 | 1 | pembrolizumab 200 mg q3w | 6.4 | false | MSS | 2026-03-15T05:36:01.344728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520141 | REC_0015605 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.3 | 67 | female | 0 | 12 | 7.4 | 1 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:36:01.345110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914864 | REC_0015606 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 10 | 63 | female | 0 | 14 | 4.8 | 3 | sotorasib 960 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:36:01.345480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675185 | REC_0015607 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.3 | 55 | female | 0 | 22 | 5.5 | 4 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:36:01.345868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767511 | REC_0015608 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 4.7 | 60 | male | 1 | 17 | 4.9 | 1 | entrectinib 600 mg daily | 19 | false | MSS | 2026-03-15T05:36:01.346257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612628 | REC_0015609 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 15.6 | 62 | male | 1 | 15 | 4.8 | 6 | sotorasib 960 mg daily | 18.4 | true | MSS | 2026-03-15T05:36:01.346652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822503 | REC_0015610 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 12 | 61 | male | 0 | 17 | 6.4 | 2 | sotorasib 960 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:36:01.347042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274042 | REC_0015611 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.6 | 63 | female | 1 | 21 | 6.1 | 3 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:01.347430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527447 | REC_0015612 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.3 | 64 | female | 1 | 14 | 4.7 | 7 | sotorasib 960 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.347834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836577 | REC_0015613 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.8 | 54 | male | 0 | 20 | 6.2 | 2 | entrectinib 600 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:36:01.348487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700266 | REC_0015614 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 9.6 | 75 | female | 1 | 6 | 6.8 | 1 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:36:01.349137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370690 | REC_0015615 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.5 | 56 | female | 0 | 12 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.8 | true | MSS | 2026-03-15T05:36:01.349578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546505 | REC_0015616 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 2.4 | 66 | female | 1 | 29 | 6.3 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:01.349943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201199 | REC_0015617 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 17.2 | 78 | female | 2 | 8 | 6.4 | 8 | entrectinib 600 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:36:01.350314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106664 | REC_0015618 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6 | 70 | male | 2 | 22 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:36:01.350666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139265 | REC_0015619 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 7.8 | 61 | female | 0 | 17 | 6.6 | 2 | entrectinib 600 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.351061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958483 | REC_0015620 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.7 | 71 | male | 0 | 13 | 4.6 | 4 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:36:01.351436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455798 | REC_0015621 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 16.2 | 72 | male | 2 | 17 | 4.8 | 1 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:01.351795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750330 | REC_0015622 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 1.9 | 68 | male | 0 | 17 | 4.8 | 5 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:36:01.352281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944982 | REC_0015623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.2 | 70 | female | 2 | 50 | 4.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.1 | true | MSS | 2026-03-15T05:36:01.352706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805157 | REC_0015624 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.6 | 72 | female | 2 | 83 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:36:01.353088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808926 | REC_0015625 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.1 | 58 | male | 1 | 16 | 6.6 | 3 | entrectinib 600 mg daily | 6.7 | true | MSS | 2026-03-15T05:36:01.353492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838944 | REC_0015626 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 5.6 | 58 | male | 1 | 19 | 7.5 | 6 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:36:01.356369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755831 | REC_0015627 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 15.4 | 78 | female | 1 | 3 | 5.5 | 6 | osimertinib 80 mg daily | 6.1 | true | MSI-H | 2026-03-15T05:36:01.359334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712273 | REC_0015628 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.2 | 71 | female | 2 | 19 | 4 | 2 | entrectinib 600 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:01.359831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853506 | REC_0015629 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 11.5 | 64 | male | 0 | 13 | 5.5 | 8 | pembrolizumab 200 mg q3w | 5.9 | true | MSI-H | 2026-03-15T05:36:01.360362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719124 | REC_0015630 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.2 | 82 | female | 2 | 60 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:36:01.361071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123865 | REC_0015631 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 7 | 74 | female | 0 | 47 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.6 | false | MSS | 2026-03-15T05:36:01.361525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549745 | REC_0015632 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 16 | 58 | female | 0 | 18 | 4.1 | 6 | alectinib 600 mg BID | 15.1 | false | MSS | 2026-03-15T05:36:01.361944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978772 | REC_0015633 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.1 | 77 | female | 2 | 20 | 4.6 | 8 | entrectinib 600 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:36:01.362363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328768 | REC_0015634 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.8 | 59 | male | 1 | 22 | 5.3 | 6 | entrectinib 600 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:01.362787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755400 | REC_0015635 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 30 | 9.8 | 73 | female | 2 | 20 | 5.7 | 0 | osimertinib 80 mg daily | 34.4 | true | MSS | 2026-03-15T05:36:01.363196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350695 | REC_0015636 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.3 | 56 | female | 1 | 10 | 4.2 | 3 | pembrolizumab 200 mg q3w | 10.4 | true | MSI-H | 2026-03-15T05:36:01.363895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988035 | REC_0015637 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 7.3 | 70 | female | 2 | 9 | 4.5 | 0 | sotorasib 960 mg daily | 31.4 | false | MSS | 2026-03-15T05:36:01.364543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671348 | REC_0015638 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 34 | 5.1 | 90 | male | 1 | 3 | 5.6 | 2 | pembrolizumab 200 mg q3w | 18.7 | false | MSS | 2026-03-15T05:36:01.365288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561419 | REC_0015639 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 35 | 15.7 | 68 | female | 0 | 12 | 6.5 | 6 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:36:01.365734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878852 | REC_0015640 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.6 | 61 | female | 1 | 20 | 7.1 | 2 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:01.366366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931099 | REC_0015641 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.8 | 79 | female | 2 | 11 | 4.8 | 1 | sotorasib 960 mg daily | 17 | false | MSS | 2026-03-15T05:36:01.366794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175067 | REC_0015642 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.7 | 72 | female | 2 | 4 | 7.1 | 3 | osimertinib 80 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:36:01.367214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188599 | REC_0015643 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12.8 | 70 | female | 2 | 16 | 4.7 | 1 | sotorasib 960 mg daily | 23 | true | MSS | 2026-03-15T05:36:01.367569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559641 | REC_0015644 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 16 | 54 | male | 0 | 9 | 5.2 | 5 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:36:01.367934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242255 | REC_0015645 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 9.7 | 67 | female | 1 | 12 | 5 | 6 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:01.368439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189650 | REC_0015646 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8.5 | 71 | female | 1 | 14 | 5.3 | 1 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:36:01.368831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166442 | REC_0015647 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.5 | 64 | male | 0 | 39 | 5.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.371396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346466 | REC_0015648 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.8 | 59 | female | 0 | 36 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.372537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111398 | REC_0015649 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.1 | 70 | female | 3 | 40 | 6.5 | 4 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:36:01.373010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593180 | REC_0015650 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.7 | 43 | female | 0 | 35 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:36:01.373370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168201 | REC_0015651 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.3 | 64 | male | 1 | 19 | 5 | 6 | alectinib 600 mg BID | 7.9 | false | MSS | 2026-03-15T05:36:01.373721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127659 | REC_0015652 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 22.8 | 76 | female | 2 | 7 | 3.4 | 8 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:01.374232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772925 | REC_0015653 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.8 | 66 | female | 1 | 13 | 3.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.374841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842221 | REC_0015654 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 13.7 | 69 | female | 0 | 24 | 5.9 | 5 | entrectinib 600 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:01.375279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681631 | REC_0015655 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 12.7 | 67 | female | 0 | 4 | 6.2 | 1 | osimertinib 80 mg daily | 18.3 | true | MSS | 2026-03-15T05:36:01.375706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232205 | REC_0015656 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.5 | 66 | female | 0 | 57 | 8.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:36:01.376249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634989 | REC_0015657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.4 | 63 | male | 0 | 22 | 7.2 | 8 | alectinib 600 mg BID | 6.6 | false | MSI-H | 2026-03-15T05:36:01.376686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583789 | REC_0015658 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 11.6 | 66 | male | 0 | 20 | 6.8 | 1 | alectinib 600 mg BID | 17.9 | false | MSS | 2026-03-15T05:36:01.377047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413876 | REC_0015659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.1 | 56 | female | 0 | 8 | 6 | 7 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:01.377398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807558 | REC_0015660 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15.8 | 58 | male | 1 | 14 | 5.9 | 2 | entrectinib 600 mg daily | 20.3 | false | MSS | 2026-03-15T05:36:01.377732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438135 | REC_0015661 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.1 | 61 | female | 1 | 32 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:36:01.378081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648212 | REC_0015662 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.8 | 67 | female | 0 | 41 | 4.2 | 1 | pembrolizumab 200 mg q3w | 19.9 | true | MSS | 2026-03-15T05:36:01.378466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227809 | REC_0015663 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.5 | 60 | male | 1 | 29 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:36:01.378848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381883 | REC_0015664 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.9 | 73 | female | 1 | 13 | 6.5 | 5 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:36:01.379256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165019 | REC_0015665 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 16.4 | 85 | female | 1 | 14 | 4.2 | 4 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:01.379657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668813 | REC_0015666 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 12.2 | 69 | female | 1 | 20 | 4.9 | 5 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:36:01.380404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519488 | REC_0015667 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15.9 | 68 | male | 0 | 28 | 6.2 | 1 | entrectinib 600 mg daily | 19.5 | true | MSS | 2026-03-15T05:36:01.381134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509954 | REC_0015668 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.6 | 74 | female | 1 | 67 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 27.2 | true | MSS | 2026-03-15T05:36:01.381810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528775 | REC_0015669 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.6 | 70 | male | 1 | 66 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:36:01.382270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263230 | REC_0015670 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 22.5 | 74 | female | 1 | 23 | 2 | 2 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:01.382692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604788 | REC_0015671 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 17.4 | 66 | male | 1 | 14 | 6.4 | 1 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:01.383087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745200 | REC_0015672 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 8.1 | 62 | female | 0 | 29 | 6.4 | 2 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:36:01.383464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121333 | REC_0015673 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 7.8 | 78 | female | 2 | 10 | 4.5 | 2 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:01.383836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193187 | REC_0015674 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 15.7 | 67 | female | 0 | 17 | 6.2 | 4 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:36:01.384302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769576 | REC_0015675 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 11.4 | 69 | female | 0 | 22 | 5.6 | 7 | osimertinib 80 mg daily | 15.5 | true | MSS | 2026-03-15T05:36:01.384703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590877 | REC_0015676 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.8 | 73 | female | 1 | 4 | 7.1 | 6 | sotorasib 960 mg daily | 17.8 | false | MSS | 2026-03-15T05:36:01.385081+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583802 | REC_0015677 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.2 | 58 | male | 1 | 20 | 4 | 6 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:36:01.387670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534326 | REC_0015678 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 8.3 | 61 | female | 1 | 15 | 6.7 | 6 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:01.388666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626991 | REC_0015679 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 12.7 | 61 | female | 1 | 10 | 4 | 6 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:01.389320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116495 | REC_0015680 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 9.1 | 61 | male | 0 | 15 | 4.8 | 0 | entrectinib 600 mg daily | 30.1 | false | MSS | 2026-03-15T05:36:01.389740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491208 | REC_0015681 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9 | 72 | female | 1 | 8 | 4.4 | 9 | entrectinib 600 mg daily | 6.8 | false | MSS | 2026-03-15T05:36:01.390130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350655 | REC_0015682 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.9 | 54 | female | 0 | 61 | 6.6 | 1 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:01.390466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282924 | REC_0015683 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 12.1 | 66 | female | 0 | 12 | 5.8 | 1 | osimertinib 80 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:36:01.390817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298121 | REC_0015684 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 14.6 | 67 | female | 1 | 20 | 6.2 | 4 | pembrolizumab 200 mg q3w | 9.9 | true | MSS | 2026-03-15T05:36:01.391160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996674 | REC_0015685 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.7 | 77 | male | 1 | 13 | 5.9 | 7 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:01.391488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164397 | REC_0015686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 4.5 | 67 | female | 1 | 10 | 5.5 | 3 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:01.391822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845625 | REC_0015687 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12.5 | 59 | male | 1 | 18 | 5.8 | 4 | sotorasib 960 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:36:01.392237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938112 | REC_0015688 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 13.4 | 71 | female | 3 | 21 | 4.4 | 2 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:36:01.392640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743961 | REC_0015689 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.1 | 66 | male | 0 | 3 | 6.2 | 7 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:36:01.393020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703879 | REC_0015690 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9 | 65 | male | 1 | 25 | 5.7 | 6 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:01.393391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347664 | REC_0015691 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.6 | 62 | female | 0 | 44 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 33.2 | true | MSS | 2026-03-15T05:36:01.393750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267653 | REC_0015692 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 4.8 | 59 | male | 1 | 15 | 5.7 | 2 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:01.394306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903629 | REC_0015693 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 15 | 7.3 | 59 | male | 1 | 9 | 5 | 0 | osimertinib 80 mg daily | 48.3 | true | MSS | 2026-03-15T05:36:01.394694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549790 | REC_0015694 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.5 | 68 | male | 1 | 18 | 5.1 | 4 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:01.395086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956608 | REC_0015695 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 9.2 | 71 | female | 1 | 20 | 5.5 | 2 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:01.395457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428737 | REC_0015696 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.4 | 72 | female | 2 | 11 | 7.1 | 6 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:36:01.395806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596905 | REC_0015697 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 17.4 | 58 | male | 1 | 4 | 6.7 | 8 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:36:01.396323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569673 | REC_0015698 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.4 | 45 | male | 0 | 20 | 3.9 | 7 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:01.396696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550706 | REC_0015699 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 11.6 | 71 | male | 2 | 12 | 5.7 | 0 | sotorasib 960 mg daily | 30.7 | true | MSI-H | 2026-03-15T05:36:01.397058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653436 | REC_0015700 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.2 | 72 | female | 1 | 19 | 6 | 6 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:01.397435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.